Key result
Bradycardia in hospitalized COVID-19 patients is linked to ~6.6-fold higher odds of mortality.
Why the study?
Bradycardia has been observed among hospitalized COVID-19 patients, but its prevalence and association with mortality have not been studied in a large multicenter cohort.
Cohort (n=1,053)
Yes
BACKGROUND: SARS-CoV2 has affected more than 73.8 million individuals. While SARS-CoV2 is considered a predominantly respiratory virus, we report a trend of bradycardia among hospitalized patients, particularly in association with mortality. METHODOLOGY: The multi-center retrospective analysis consisted of 1053 COVID-19 positive patients from March to August 2020. A trend of bradycardia was noted in the study population. Absolute bradycardia and profound bradycardia was defined as a sustained heart rate < 60 BPM and < 50 BPM, respectively, on two separate occasions, a minimum of 4 h apart during hospitalization. Each bradycardic event was confirmed by two physicians and exclusion criteria included: less than 18 years old, end of life bradycardia, left AMA, or taking AV Nodal blockers. Data was fetched using a SQL program through the EMR and data was analyzed using SPSS 27.0. A logistic regression was done to study the effect of bradycardia, age, gender, and BMI on mortality in the study group. RESULTS: (5)=47.10, p < .001. For each year of age > 18, the odds of dying increased 1.048 times (95% CI [1.25-5.27]). CONCLUSION: The incidence of absolute bradycardia was found in 24.9% of the study cohort and these individuals were found to have a significant increase in mortality.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2021) conducted a cohort in COVID-19 (n=1,053). Absolute bradycardia (Heart rate < 60 BPM) vs. Normal heart rate was evaluated on Mortality (OR 6.59, 95% CI 2.83-15.36, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: